• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » TLC Biopharmaceuticals reports results of phase I/II tlc599 osteoarthritis trial

TLC Biopharmaceuticals reports results of phase I/II tlc599 osteoarthritis trial

January 11, 2017
CenterWatch Staff

TLC has reported top-line results from the phase I/II trial of TLC599 for sustained pain management in patients with osteoarthritis of the knee. The trial demonstrated a positive safety profile for a single intra-articular injection of either a 6mg or 12mg dose of TLC599. In addition, the trial demonstrated a trend of sustained, clinically meaningful decrease from baseline through week 12 in several widely-used assessments of pain. These results support the potential for TLC599 to address the problem of a limited duration of action for steroid therapy in patients with osteoarthritis. 

Therapies for osteoarthritis can be divided into approximately three categories depending on the severity of the disease. Often, physical therapy and non-steroidal anti-inflammatory drugs are used at early stages. As the disease progresses, injectable steroids are a typical treatment option. However, clinical practice guidelines advise against administering injections more than four times a year. These steroids only last for one to two weeks, meaning that many patients suffer from pain for months in between treatments. 

“Aging populations across the globe are leading to an increased prevalence of osteoarthritis but current treatment options are inadequate,” commented TLC President George Yeh. “The results of this trial demonstrate that TLC599 may address the critical issue of short duration of action that limits the therapeutic potential of corticosteroid treatments in wide use today. We are encouraged by these results as we move ahead with our phase II trial. We are optimistic that TLC599 will ultimately reduce burdens for patients and the healthcare system.” 

The randomized, open-label, single-dose study of 40 patients found no significant adverse events over the 12 week period following injection. In addition, results in the 12mg dose group demonstrated a trend of decrease from baseline in subject-rated Visual Analogue Scale (VAS) pain score at each study evaluation at week one, four, eight and 12 (with a -3.14 point mean change from baseline at week 12; p=0.0156; per-protocol (PP) population), consistent with results in patients treated with the 6mg dose (-1.95 point mean change from baseline at week 12; p=0.3125; PP). Results also demonstrated a trend of decrease relative to baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) A pain subset measurement at each study evaluation (a mean change of -3.75 points at week 12; p=0.0625; PP). These measurements were consistent with the trend observed in patients treated with the 6mg dose (a mean change of -1.5 points from baseline in WOMAC A score; p=0.2500; PP). The positive safety profile and sustained efficacy observed in the trial support the potential of TLC599 for further development at 12mg or higher doses. 

TLC plans to initiate a phase II trial of TLC599 at sites in Taiwan and Australia, with investigational new drug (IND) approval already granted in Taiwan by the Taiwan Food and Drug Administration (TFDA). The trial will involve 24 weeks of observation following a single intra-articular injection of TLC599 and investigate sustained control of pain for three groups: placebo, 12mg and 18mg, with 24 patients in each group. WOMAC measurements will be conducted at regular intervals over the observation period to evaluate efficacy of pain management. Data will be un-blinded once the 24 week data are available for all 72 patients. This phase II clinical trial will help to determine the sample size and the efficacy period for a pivotal trial. 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing